Skip to main content

Table 3 Univariate and multivariate competing risk regression analyses for local failure (n = 156)

From: Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases

 

Univariate analysis

Multivariate analysis

 

HR (95% CI)

p value

HR (95% CI)

p value

Number of BMs

A (1)

0.98 (0.39–2.74)

0.960

0.96 (0.30–3.04)

0.940

B (2–4)

Ref

–

Ref

–

C (5–10)

0.56 (0.12–2.59)

0.460

0.54 (0.11–2.70)

0.450

Age (years)

 < 65

Ref

–

Ref

–

 ≥ 65

0.71 (0.29–1.76)

0.460

0.70 (0.22–2.26)

0.550

Gender

Female

Ref

–

Ref

–

Male

2.09 (0.81–5.36)

0.130

2.48 (0.80–7.66)

0.110

Primary site

Lung

0.37 (0.08–1.64)

0.190

0.20 (0.03–1.18)

0.075

GI

0.40 (0.56–2.91)

0.370

0.26 (0.03–2.55)

0.250

Breast

Ref

–

Ref

–

Others

0.59 (0.11–3.06)

0.530

0.33 (0.05–2.09)

0.240

KPS

 ≥ 80

Ref

–

Ref

–

 ≤ 70

1.60 (0.67–3.81)

0.290

1.45 (0.49–4.30)

0.510

Extracranial lesions

Controlled

Ref

–

Ref

–

Uncontrolled

0.35 (0.14–0.83)

0.018

0..30 (0.10–0.93)

0.037

fSRT or SRS

SRS

Ref

–

Ref

–

fSRT

3.45 (1.37–8.90)

0.009

1.24 (0.29–5.40)

0.770

Total PTV volume (cm3)

1 (≥ 15)

5.50 (1.76–17.19)

0.003

4.05 (0.90–

0.068

2 (≥ 4, < 15)

1.78 (0.51–6.15)

0.360

1.47 (0.36–6.07)

0.590

3 (< 4)

Ref

–

Ref

–

  1. BMs Brain metastases, GI Gastrointestinal cancers, KPS Karnofsky performance status, fSRT Fractionated stereotactic radiotherapy, SRS Stereotactic radiosurgery, PTV Planning target volume
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us